The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing.
Drug repurposing against COVID-19. focus on anticancer agents / Ciliberto, Gennaro; Mancini, Rita; Paggi, Marco G. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020), p. 86. [10.1186/s13046-020-01590-2]
Drug repurposing against COVID-19. focus on anticancer agents
Mancini, RitaConceptualization
;
2020
Abstract
The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing.File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mancini_Drug-repurposing-against-COVID19.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
906.89 kB
Formato
Adobe PDF
|
906.89 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
